4 Healthcare Stock Stories Prescribed for Investors

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

AstraZeneca Group (NYSE:AZN): Closing price $50.35

On Tuesday, the firm said that the United States District Court for the District of New Jersey ruled that its United States Patent No. 6,598,603, protecting Pulmicort Respules in the U.S., is invalid. Beyond that, the Court decided that the generic defendants involved in the litigation do not infringe AstraZeneca’s second patent, Patent No. 7,524,834. Executive Vice President, North America, Paul Hudson responed that “AstraZenca strongly disagrees with the Court’s decision. AstraZeneca has full confidence in the strength of its intellectual property rights protecting Pulmicort Respules. AstraZeneca is considering next steps, including an appeal of the Court’s decision.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AZN

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business